Fig. 3From: Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patientsSurvival analysis of NSCLC patients with KRAS and KRAS G12C mutations. Overall survival (OS) analysis of KRAS mutation and wildtype tumors a. OS analysis of KRAS G12C mutation and wildtype tumors b. m: months; wt: wild type; HR: hazard ratio; CI: confidence intervalBack to article page